Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1603-1610

  Egawa Takata, Tomomi ^a   Ueda, Yutaka ^a   Kuragaki, Chie ^a   Miyake, Takahito ^a,b   Miyatake, Takashi ^a   Fujita, Masami ^a   Yoshino, Kiyoshi ^a   Nakashima, Ryuichi ^a   Okazawa, Mika ^a,c   Tsutsui, Tateki ^a   Morishige, Ken Ichirou ^a   Kimura, Tadashi ^a   Yamasaki, Masato ^b   Nishizaki, Takamichi ^d   Nagamatsu, Masaaki ^c   Ito, Kimihiko ^e   Asada, Masahiro ^f   Ogita, Kazuhide ^g   Wakimoto, Akinori ^h   Yamamoto, Toshiya ⁱ   Nishio, Yukihiro ^j   Enomoto, Takayuki ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c Kaizuka City Hospital   (Japan)

^d Suita Municipal Hospital   (Japan)

^e KANSAI ROSAI HOSPITAL   (Japan)

^f Itami City Hospital   (Japan)

^g Rinku General Medical Center   (Japan)

^h OSAKA KOSEI NENKIN HOSPITAL   (Japan)

ⁱ SAKAI MUNICIPAL HOSPITAL   (Japan)

^j OSAKA POLICE HOSPITAL   (Japan)

more..

Author keywords

Carboplatin; Combination chemotherapy; Endometrial cancer; Epirubicin; Paclitaxel; TEC

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLACTIC SHOCK; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GENITAL BLEEDING; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK FACTOR; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERUS SURGERY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 82455167994     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1638-4     Document Type: Article

References (15)

1. CP Morrow, et al. 1991 Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study Gynecol Oncol 40 1 55 65 1989916 10.1016/0090-8258(91)90086-K 1:STN:280:DyaK3M7hsFaitA%3D%3D
2. A Mariani, et al. 2002 Assessment of prognostic factors in stage IIIA endometrial cancer Gynecol Oncol 86 1 38 44 12079298 10.1006/gyno.2002.6713 (Pubitemid 34757049)
3. ME Randall, et al. 2006 Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 24 1 36 44 16330675 10.1200/JCO.2004.00.7617 1:CAS:528:DC%2BD28Xot1Chug%3D%3D (Pubitemid 46630491)
4. GF Fleming, et al. 2004 Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 22 11 2159 2166 15169803 10.1200/JCO.2004.07.184 1:CAS:528:DC%2BD2cXpsVWltrw%3D (Pubitemid 41095150)
5. A Lissoni, et al. 1997 Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma Ann Oncol 8 10 969 972 9402169 10.1023/A:1008221310453 1:STN:280:DyaK1c%2FmtlOlsw%3D%3D (Pubitemid 27475727)
6. CA Papadimitriou, et al. 2008 Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a hellenic co-operative oncology group (HeCOG) study Gynecol Oncol 110 1 87 92 18455782 10.1016/j.ygyno.2008.03. 004 1:CAS:528:DC%2BD1cXnvVOksrk%3D
7. C Le Tourneau JJ Lee LL Siu 2009 Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 10 708 720 19436029 10.1093/jnci/djp079 1:CAS:528:DC%2BD1MXmtlyit7w%3D
8. MA Sovak, et al. 2006 Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study Gynecol Oncol 103 2 451 457 16677690 10.1016/j.ygyno.2006. 03.019 1:CAS:528:DC%2BD28XhtFegtbbL (Pubitemid 44740097)
9. N Susumu, et al. 2008 Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese gynecologic oncology group study Gynecol Oncol 108 1 226 233 17996926 10.1016/j.ygyno.2007.09.029 1:CAS:528:DC%2BD1cXhtlShsw%3D%3D (Pubitemid 350299451)
10. R Maggi, et al. 2006 Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial Br J Cancer 95 3 266 271 16868539 10.1038/sj.bjc.6603279 1:STN:280:DC%2BD28vovV2kug%3D%3D (Pubitemid 44187586)
11. T Hogberg 2008 Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials Clin Oncol (R Coll Radiol) 20 6 463 469 10.1016/j.clon.2008.04.001 1:STN:280:DC%2BD1cvjtFeisQ%3D%3D
12. JT Thigpen, et al. 2004 Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 22 19 3902 3908 15459211 10.1200/JCO.2004.02.088 1:CAS:528:DC%2BD2cXpsVKitr8%3D (Pubitemid 41079871)
13. FM Muggia, et al. 1997 Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 3 987 993 9060537 1:CAS:528: DyaK2sXitFCgs7k%3D (Pubitemid 27106281)
14. PF Escobar, et al. 2003 Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer J Cancer Res Clin Oncol 129 11 651 654 14505047 10.1007/s00432-003-0497-8 1:CAS:528:DC%2BD3sXosVGju70%3D (Pubitemid 37452631)
15. FM Muggia, et al. 2002 Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study J Clin Oncol 20 9 2360 2364 11981008 10.1200/JCO.2002.08. 171 1:CAS:528:DC%2BD38XktVKrs7Y%3D (Pubitemid 34441664)